Inflammatory Skin Diseases Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under development and key players involved in therapeutic development for acne vulgaris, rosacea and chronic urticaria (also known as hives). It also features dormant and discontinued products.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. There are 60 products in development for this indication, and companies operating in this space include Cassiopea and Elorac.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. There are 18 products in development for this indication, and companies operating in this space include Dermata Therapeutics and Promius Pharma.

Chronic urticaria, also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. There are 17 products in development for this indication, and companies operating in this space include GlaxoSmithKline and Novartis.

Molecular targets acted on by products in development for inflammatory skin disorders include cytokines, ribosomal RNA and retinoic acid receptors.

Scope

– Which companies are the most active within each pipeline?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

3SBio Inc

Acne Vulgaris

BioPharmX Inc

Braintree Laboratories Inc

Cassiopea SpA

Cutanea Life Sciences Inc

Daewoong Co Ltd

Deltanoid Pharmaceuticals Inc

ELORAC Inc

Foamix Pharmaceuticals Ltd

Galderma SA

Helix BioMedix Inc

Innovation Pharmaceuticals Inc

Lee’s Pharmaceutical Holdings Ltd

LEO Pharma A/S

Melinta Therapeutics Inc

Novabiotics Ltd

Novan Inc

Novartis AG

Paratek Pharmaceuticals Inc

Pfizer Inc

Phagelux Inc

Phosphagenics Ltd

Photocure ASA

Promius Pharma LLC

Provectus Biopharmaceuticals Inc

Realm Therapeutics Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Sol-GelTechnologiesLtd

Sun Pharmaceutical Industries Ltd

Valeant Pharmaceuticals International Inc

Vyome Biosciences Pvt Ltd

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 Inflammatory Skin Diseases Report Coverage 7

2.2 Acne Vulgaris - Overview 7

2.3 Rosacea - Overview 7

2.4 Chronic Urticaria Or Hives - Overview 7

3 Therapeutics Development 8

3.1 Acne Vulgaris 8

3.2 Rosacea 15

3.3 Chronic Urticaria Or Hives 19

4 Therapeutics Assessment 23

4.1 Acne Vulgaris 23

4.2 Rosacea 30

4.3 Chronic Urticaria Or Hives 38

5 Companies Involved in Therapeutics Development 45

5.1 Acne Vulgaris 45

5.2 Rosacea 61

5.3 Chronic Urticaria Or Hives 66

6 Dormant Projects 71

6.1 Acne Vulgaris 71

6.2 Rosacea 75

6.3 Chronic Urticaria Or Hives 76

7 Discontinued Products 77

7.1 Acne Vulgaris 77

7.2 Rosacea 77

7.3 Chronic Urticaria Or Hives 78

8 Product Development Milestones 79

8.1 Acne Vulgaris 79

8.2 Rosacea 90

8.3 Chronic Urticaria Or Hives 101

9 Appendix 112

9.1 Methodology 112

9.2 Coverage 112

9.3 Secondary Research 112

9.4 Primary Research 112

9.5 Expert Panel Validation 112

9.6 Contact Us 113

9.7 Disclaimer 113

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Acne Vulgaris 8

Table 2: Number of Products under Development by Companies, Acne Vulgaris 10

Table 3: Number of Products under Development by Universities/Institutes, Acne Vulgaris 11

Table 4: Products under Development by Companies, Acne Vulgaris 12

Table 5: Products under Development by Universities/Institutes, Acne Vulgaris 14

Table 6: Number of Products under Development for Rosacea 15

Table 7: Number of Products under Development by Companies, Rosacea 17

Table 8: Products under Development by Companies, Rosacea 18

Table 9: Number of Products under Development for Chronic Urticaria Or Hives 19

Table 10: Number of Products under Development by Companies, Chronic Urticaria Or Hives 21

Table 11: Products under Development by Companies, Chronic Urticaria Or Hives 22

Table 12: Number of Products by Stage and Target, Acne Vulgaris 24

Table 13: Number of Products by Stage and Mechanism of Action, Acne Vulgaris 26

Table 14: Number of Products by Stage and Route of Administration, Acne Vulgaris 28

Table 15: Number of Products by Stage and Molecule Type, Acne Vulgaris 30

Table 16: Number of Products by Stage and Target, Rosacea 32

Table 17: Number of Products by Stage and Mechanism of Action, Rosacea 34

Table 18: Number of Products by Stage and Route of Administration, Rosacea 36

Table 19: Number of Products by Stage and Molecule Type, Rosacea 38

Table 20: Number of Products by Stage and Target, Chronic Urticaria Or Hives 39

Table 21: Number of Products by Stage and Mechanism of Action, Chronic Urticaria Or Hives 41

Table 22: Number of Products by Stage and Route of Administration, Chronic Urticaria Or Hives 42

Table 23: Number of Products by Stage and Molecule Type, Chronic Urticaria Or Hives 44

Table 24: Acne Vulgaris – Pipeline by 3SBio Inc, 45

Table 25: Acne Vulgaris – Pipeline by BioPharmX Inc, 45

Table 26: Acne Vulgaris – Pipeline by Braintree Laboratories Inc, 46

Table 27: Acne Vulgaris – Pipeline by Cassiopea SpA, 46

Table 28: Acne Vulgaris – Pipeline by Cutanea Life Sciences Inc, 47

Table 29: Acne Vulgaris – Pipeline by Daewoong Co Ltd, 47

Table 30: Acne Vulgaris – Pipeline by Deltanoid Pharmaceuticals Inc, 48

Table 31: Acne Vulgaris – Pipeline by ELORAC Inc, 48

Table 32: Acne Vulgaris – Pipeline by Foamix Pharmaceuticals Ltd, 49

Table 33: Acne Vulgaris – Pipeline by Galderma SA, 49

Table 34: Acne Vulgaris – Pipeline by Helix BioMedix Inc, 50

Table 35: Acne Vulgaris – Pipeline by Innovation Pharmaceuticals Inc, 50

Table 36: Acne Vulgaris – Pipeline by Lee’s Pharmaceutical Holdings Ltd, 51

Table 37: Acne Vulgaris – Pipeline by LEO Pharma A/S, 51

Table 38: Acne Vulgaris – Pipeline by Melinta Therapeutics Inc, 52

Table 39: Acne Vulgaris – Pipeline by Novabiotics Ltd, 52

Table 40: Acne Vulgaris – Pipeline by Novan Inc, 53

Table 41: Acne Vulgaris – Pipeline by Novartis AG, 53

Table 42: Acne Vulgaris – Pipeline by Paratek Pharmaceuticals Inc, 54

Table 43: Acne Vulgaris – Pipeline by Pfizer Inc, 54

Table 44: Acne Vulgaris – Pipeline by Phagelux Inc, 55

Table 45: Acne Vulgaris – Pipeline by Phosphagenics Ltd, 55

Table 46: Acne Vulgaris – Pipeline by Photocure ASA, 56

Table 47: Acne Vulgaris – Pipeline by Promius Pharma LLC, 56

Table 48: Acne Vulgaris – Pipeline by Provectus Biopharmaceuticals Inc, 57

Table49:AcneVulgaris-PipelinebyRealmTherapeuticsPlc, 57

Table50: Acne Vulgaris – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 58

Table51: Acne Vulgaris – Pipeline by Sol-Gel Technologies Ltd, 58

Table52: Acne Vulgaris – Pipeline by Sun Pharmaceutical Industries Ltd, 59

Table 53: Acne Vulgaris – Pipeline by Valeant Pharmaceuticals International Inc, 59

Table 54: Acne Vulgaris – Pipeline by Vyome Biosciences Pvt Ltd, 60

Table 55: Acne Vulgaris – Pipeline by XBiotech Inc, 60

Table 56: Rosacea – Pipeline by Almirall SA, 61

Table 57: Rosacea – Pipeline by Amorepacific Corp, 63

Table 58: Rosacea – Pipeline by BioPharmX Inc, 63

Table 59: Rosacea – Pipeline by Cutanea Life Sciences Inc, 63

Table 60: Rosacea – Pipeline by ELORAC Inc, 64

Table 61: Rosacea – Pipeline by Foamix Pharmaceuticals Ltd, 64

Table 62: Rosacea – Pipeline by Hovione FarmaCiencia SA, 66

Table 63: Rosacea – Pipeline by Promius Pharma LLC, 66

Table 64: Rosacea – Pipeline by Sol-Gel Technologies Ltd, 66

Table 65: Chronic Urticaria Or Hives – Pipeline by ELORAC Inc, 68

Table 66: Chronic Urticaria Or Hives – Pipeline by F. Hoffmann-La Roche Ltd, 68

Table 67: Chronic Urticaria Or Hives – Pipeline by Faes Farma SA, 69

Table 68: Chronic Urticaria Or Hives – Pipeline by Fountain Biopharma Inc, 69

Table 69: Chronic Urticaria Or Hives – Pipeline by Genentech Inc, 70

Table 70: Chronic Urticaria Or Hives – Pipeline by GlaxoSmithKline Plc, 70

Table 71: Chronic Urticaria Or Hives – Pipeline by Glenmark Pharmaceuticals Ltd, 71

Table 72: Chronic Urticaria Or Hives – Pipeline by Mycenax Biotech Inc, 72

Table 73: Chronic Urticaria Or Hives – Pipeline by Novartis AG, 72

Table 74: Chronic Urticaria Or Hives – Pipeline by Synermore Biologics Co Ltd, 73

Table 75: Acne Vulgaris – Dormant Projects, 74

Table 76: Rosacea – Dormant Projects, 80

Table 77: Chronic Urticaria Or Hives – Dormant Projects, 82

Table 78: Acne Vulgaris – Discontinued Products, 83

Table 79: Rosacea – Discontinued Products, 83

Table 80: Chronic Urticaria Or Hives – Discontinued Products, 84

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Acne Vulgaris 8

Figure 2: Number of Products under Development by Companies, Acne Vulgaris 9

Figure 3: Number of Products under Development for Rosacea 15

Figure 4: Number of Products under Development by Companies, Rosacea 16

Figure 5: Number of Products under Development for Chronic Urticaria Or Hives 19

Figure 6: Number of Products under Development by Companies, Chronic Urticaria Or Hives 20

Figure 7: Number of Products by Top 10 Targets, Acne Vulgaris 23

Figure 8: Number of Products by Stage and Top 10 Targets, Acne Vulgaris 23

Figure 9: Number of Products by Top 10 Mechanism of Actions, Acne Vulgaris 25

Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Acne Vulgaris 25

Figure 11: Number of Products by Routes of Administration, Acne Vulgaris 27

Figure 12: Number of Products by Stage and Routes of Administration, Acne Vulgaris 27

Figure 13: Number of Products by Molecule Types, Acne Vulgaris 29

Figure 14: Number of Products by Stage and Molecule Types, Acne Vulgaris 29

Figure 15: Number of Products by Top 10 Targets, Rosacea 30

Figure 16: Number of Products by Stage and Top 10 Targets, Rosacea 31

Figure 17: Number of Products by Top 10 Mechanism of Actions, Rosacea 33

Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Rosacea 33

Figure 19: Number of Products by Routes of Administration, Rosacea 35

Figure 20: Number of Products by Stage and Routes of Administration, Rosacea 35

Figure 21: Number of Products by Molecule Types, Rosacea 37

Figure 22: Number of Products by Stage and Molecule Types, Rosacea 37

Figure 23: Number of Products by Targets, Chronic Urticaria Or Hives 38

Figure 24: Number of Products by Stage and Targets, Chronic Urticaria Or Hives 39

Figure 25: Number of Products by Mechanism of Actions, Chronic Urticaria Or Hives 40

Figure 26: Number of Products by Stage and Mechanism of Actions, Chronic Urticaria Or Hives 40

Figure 27: Number of Products by Routes of Administration, Chronic Urticaria Or Hives 41

Figure 28: Number of Products by Stage and Top 10 Routes of Administration, Chronic Urticaria Or Hives 42

Figure 29: Number of Products by Molecule Types, Chronic Urticaria Or Hives 43

Figure 30: Number of Products by Stage and Molecule Types, Chronic Urticaria Or Hives 43

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports